Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 15;8(5):172-186.
doi: 10.4239/wjd.v8.i5.172.

Effects of glycaemic management on diabetic kidney disease

Richard J MacIsaac  1 , George Jerums  1 , Elif I Ekinci  1
Affiliations
Review

Effects of glycaemic management on diabetic kidney disease

Richard J MacIsaac et al. World J Diabetes. .

Abstract

Hyperglycaemia contributes to the onset and progression of diabetic kidney disease (DKD). Observational studies have not consistently demonstrated a glucose threshold, in terms of HbA1c levels, for the onset of DKD. Tight glucose control has clearly been shown to reduce the incidence of micro- or macroalbuminuria. However, evidence is now also emerging to suggest that intensive glucose control can slow glomerular filtration rate loss and possibly progression to end stage kidney disease. Achieving tight glucose control needs to be balanced against the increasing appreciation that glucose _targets for the prevention of diabetes related complications need be individualised for each patient. Recently, empagliflozin which is an oral glucose lowering agent of the sodium glucose cotransporter-2 inhibitor class has been shown to have renal protective effects. However, the magnitude of empagliflozin's reno-protective properties are over and above that expected from its glucose lowering effects and most likely largely result from mechanisms involving alterations in intra-renal haemodynamics. Liraglutide and semaglutide, both injectable glucose lowering agents which are analogues of human glucagon like peptide-1 have also been shown to reduce progression to macroalbuminuria through mechanisms that remain to be fully elucidated. Here we review the evidence from observational and interventional studies that link good glucose control with improved renal outcomes. We also briefly review the potential reno-protective effects of newer glucose lowering agents.

Keywords: Albuminuria; Chronic kidney disease; Diabetes; Diabetic nephropathy; Empagliflozin; Glomerular filtration rate; Glucose control; Liraglutide; Semaglutide.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: Professor MacIsaac RJ has received honoraria and travel support for lectures from Eli lily, Novo Nordisk, Sanofi Aventis, Astra Zeneca, Merck Sharp and Dohme and Norvartis; he has received research grants from Novo Nordisk and Sevier in the past.

Figures

Figure 1
Figure 1
Renal outcomes in the trial Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome. 1Four-point renal outcome = progression to macroalbuminuria, doubling of serum creatinine, initiation of RRT or death from renal disease; 2Macroalbuminuria = albumin to creatinine ratio > 30 mg/mmol; 3Plus eGFR < 45 mL/min per 1.73 m2. eGFR: Estimated glomerular filtration rate; HR: Hazard ratio; NS: Non statistically significant; RRT: Renal replacement therapy.
Figure 2
Figure 2
Cardiovascular outcomes in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome (A) and cardiovascular safety trial of empagliflozin (B) studies according to estimated glomerular filtration rate. MACE: Major adverse cardiovascular event; eGFR: Estimated glomerular filtration rate; HR: Hazard ratio.
Figure 3
Figure 3
Renal outcomes in the cardiovascular safety trial of empagliflozin study. 1Four-point renal outcome = progression to macroalbuminuria plus three-point renal outcome; 2Three-point renal outcome = doubling of serum creatinine, initiation of RRT or death from renal disease; 3Macroalbuminuria = albumin to creatinine ratio > 30 mg/mmol; 4Plus eGFR < 45 mL/min per 1.73 m2. HR: Hazard ratio; eGFR: Estimated glomerular filtration rate; CV: Cardiovascular; RRT: Renal replacement therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. ADA Standards of Medical Care in Diabetes-2016: Summary of Revisions. Diabetes Care. 2016;39 Suppl 1:S4–S5. - PubMed
    1. Cooper ME. Diabetes: treating diabetic nephropathy-still an unresolved issue. Nat Rev Endocrinol. 2012;8:515–516. - PubMed
    1. Shurraw S, Tonelli M. Intensive glycemic control in type 2 diabetics at high cardiovascular risk: do the benefits justify the risks? Kidney Int. 2013;83:346–348. - PubMed
    1. de Borst MH, Navis G. Diabetes: Risks of strict glycaemic control in diabetic nephropathy. Nat Rev Nephrol. 2015;11:5–6. - PubMed
    1. Fioretto P, Barzon I, Mauer M. Is diabetic nephropathy reversible? Diabetes Res Clin Pract. 2014;104:323–328. - PubMed

LinkOut - more resources

  NODES
Association 1
twitter 2